Raycaster sells trust via validators
Raycaster
This shows Raycaster is selling trust before it sells full automation. In drug development, a wrong edit in a quality or regulatory document can trigger weeks of rework, so customers want a former CMC lead, QA reviewer, or regulatory writer checking the system’s output before they rely on it. That human layer helps Raycaster land high stakes accounts, collect labeled feedback, and turn messy customer workflows into repeatable software modules.
-
Raycaster describes a three step rollout model. Engineers map the workflow, outside domain experts validate outputs, then product telemetry from edits, tool calls, and pass fail history improves the system. Validators are not just labor, they are the bridge from services work to a durable product loop.
-
The experts Raycaster pulls in are concrete operators, former CMC, QA, and regulatory writing specialists. In practice, they review draft specs, tech transfer packs, change control narratives, and Module 3 content, the exact documents where biotech teams are most sensitive to unverifiable AI edits.
-
This also explains the competitive split. Raycaster sits above systems of record like Veeva Vault and IQVIA tools, where compliant storage and audit history already live. Large incumbents now ship their own AI agents inside those systems, so Raycaster has to win on workflow setup, evaluator loops, and customer specific context rather than generic document AI.
The likely next step is for Raycaster to shrink the amount of expert review needed per workflow. As more validator judgments get converted into templates, rules, and evaluation datasets, the company can move from concierge validation on flagship accounts toward faster deployment, higher gross margins, and a stronger position against Veeva and IQVIA inside document heavy biotech operations.